Fort Lauderdale, Fla., Aug. 16, 2018 (GLOBE NEWSWIRE) -- In a milestone transaction, a major pharmaceutical company based in China will undertake a multisite clinical study using TrialMaster EDC Suite and Acuity Analytics, from OmniComm Systems, Inc., (OTCQX: OMCM), a leading global provider of clinical data management technology.
With eClinical solutions from OmniComm and related services, the pharmaceutical company will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial of a treatment for a well-known cognitive disorder. The trial represents the sponsor’s first use of TrialMaster and Acuity for a study. TrialMaster is the mobile-friendly, easy-to-use electronic data capture solution for Phase I - IV clinical trials. Acuity Analytics provides data aggregation, analytics and visualization tools.
OmniComm was selected based on TrialMaster’s inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. Deploying studies in an efficient, timely and cost-effective manner was especially important. OmniComm’s robust, state-of-the art, compliant hosting environment was another critical factor in the selection process. Additionally, the pharmaceutical company selected Acuity because the product provides data visualization to manage the study and data analytics to make faster decisions.
“Building upon our significant traction in early phase trials, this award represents a major milestone for OmniComm, with a second sponsor in China this year now choosing to move to TrialMaster,” said Kuno van der Post, Ph.D., chief commercial officer from OmniComm. “Moreover, we are pleased with the selection of the Acuity data visualization tool, which is integrated with TrialMaster and can also support local languages.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. With an extensive global experience from more than 6,000 clinical trials, OmniComm provides comprehensive solutions for clinical research. Please visit www.omnicomm.com for more information.
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact InfoKuno van der Post, Ph.D. OmniComm Systems, Inc. +1.954.473.1254KvanderPost@omnicomm.com